NICE updates guidance and extends use of omalizumab in severe allergic asthma

Omalizumab (Xolair) has been accepted by NICE for broader use in the treatment of severe persistent immunoglobulin E (IgE)-mediated asthma.

Previously treatment with omalizumab could only be initiated on the NHS if the patient had severe exacerbations which required hospital admission (pictured) | SCIENCE PHOTO LIBRARY
Previously treatment with omalizumab could only be initiated on the NHS if the patient had severe exacerbations which required hospital admission (pictured) | SCIENCE PHOTO LIBRARY

It can now be used on the NHS for adults and children from 6 years of age who need continuous or frequent treatment with oral corticosteroids (≥4 courses in the previous year), provided the manufacturer supplies it with the discount agreed in the patient access scheme.

Omalizumab must be used as an add-on to optimised standard therapy, defined as a full trial of (and, if tolerated, documented compliance with) inhaled high-dose corticosteroids, long-acting ß2-agonists, leukotriene receptor antagonists, theophylline, oral corticosteroids and smoking cessation if clinically appropriate.

In its assessment, NICE noted the ‘life-changing’ effect of omalizumab reported by patients and concluded that omalizumab as an add-on to optimised standard therapy is more clinically effective in treating severe persistent allergic asthma than optimised standard therapy alone, leading to a reduction in total emergency visits (including hospital admissions, A&E visits and unscheduled GP visits) in adults, reduced hospital admissions in children, improved lung function in adults and a reduction in the frequency and use of rescue medication and oral corticosteroids.

View Xolair drug record

NICE guidance on omalizumab


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.